PTC Therapeutics has sold its rare pediatric disease priority review voucher (PRV) for $150 million, following FDA approval ...
Shares of PTC Inc. (NASDAQ:PTC – Get Free Report) have earned a consensus recommendation of “Moderate Buy” from the twelve brokerages that are presently covering the firm, MarketBeat.com reports. Four ...
PTC Therapeutics, Inc. (NASDAQ:PTCT – Get Free Report) reached a new 52-week high during mid-day trading on Wednesday after Robert W. Baird raised their price target on the stock from $48.00 to $52.00 ...
PTC Therapeutics' Phase II trial for utreloxastat in ALS failed to meet its primary endpoint, showing no significant ...
PTC Therapeutics, Inc. (NASDAQ:PTCT – Get Free Report)’s share price rose 4.8% on Tuesday after Robert W. Baird raised their price target on the stock from $48.00 to $52.00. Robert W. Baird currently ...
PTC Therapeutics (NASDAQ:PTCT) said a Phase 2 placebo-controlled study of its ALS drug candidate utreloxastat failed to meet ...
That's PTC's (NASDAQ: PTC) raison d'etre, and the company looks set for solid growth for many years. Moreover, despite a 57% appreciation, the stock's valuation remains highly attractive for ...
Below is Validea's guru fundamental report for PTC INC (PTC). Of the 22 guru strategies we follow, PTC rates highest using our P/B Growth Investor model based on the published strategy of Partha ...
However, on the same day, Robert W. Baird maintained a Buy rating on PTC Therapeutics (NASDAQ: PTCT). The company has a one-year high of $46.98 and a one-year low of $20.75. Currently, PTC ...
PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today that it has entered into an agreement to sell its Rare Pediatric Disease Priority Review Voucher (PRV) for $150 million upon the closing of the ...
Covestor Ltd lifted its stake in shares of PTC Inc. (NASDAQ:PTC – Free Report) by 70.8% in the 3rd quarter, according to the ...
J.P. Morgan said its top biotech picks for 2025 were Vertex (NASDAQ:VRTX), Travere (NASDAQ:TVTX), SpringWorks (NASDAQ:SWTX), ...